Improvement of Systemic Human Immunodeficiency Virus-Related Non-Hodgkin Lymphoma Outcome in the Era of Highly Active Antiretroviral Therapy

Emanuela Vaccher, Michele Spina, Renato Talamini, Martina Zanetti, Giampiero Di Gennaro, Guglielmo Nasti, Marcello Tavio, Daniele Bernardi, Cecilia Simonelli, Umberto Tirelli

Research output: Contribution to journalArticle

Abstract

To assess the impact of highly active antiretroviral therapy (HAART) on the outcome of systemic human immunodeficiency virus-related non-Hodgkin lymphoma (HIV-NHL), we retrospectively analyzed 235 patients in whom HIV-NHL was diagnosed from April 1988 through December 1999. A multivariate Cox proportional hazards model was used to estimate prognostic factors for overall survival (OS), progression-free survival (PFS), and disease-free survival (DFS). Complete remission occurred in 49% of patients, and the 3-year rates of OS, PFS, and DFS were 19%, 49%, and 73%, respectively. The greatest risk for shortened OS, PFS, and DFS was associated with no HAART use (compared with long-term HAART use); hazard ratios were 17.42 (95% confidence interval [CI], 17.42-40.25), 9.11 (95% CI, 3.71-22.32), and 8.54 (95% CI, 1.19-61.11), respectively. Our study suggests that the long-term use of HAART may favorably change the outcome for patients with systemic HIV-NHL.

Original languageEnglish
Pages (from-to)1556-1564
Number of pages9
JournalClinical Infectious Diseases
Volume37
Issue number11
DOIs
Publication statusPublished - Dec 1 2003

ASJC Scopus subject areas

  • Immunology

Fingerprint Dive into the research topics of 'Improvement of Systemic Human Immunodeficiency Virus-Related Non-Hodgkin Lymphoma Outcome in the Era of Highly Active Antiretroviral Therapy'. Together they form a unique fingerprint.

  • Cite this